High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody - Université de Bourgogne
Article Dans Une Revue Brain - A Journal of Neurology Année : 2016

High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody

Valérie Jooste
  • Fonction : Auteur
  • PersonId : 906756
Laurent Gilardin
Lucile Musset
  • Fonction : Auteur
Jean-Luc Charuel
  • Fonction : Auteur
Bruno Eymard
Olivier Fain

Résumé

Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients.

Dates et versions

hal-01409979 , version 1 (06-12-2016)

Identifiants

Citer

Yves Allenbach, Jeremy Keraen, Anne-Marie Bouvier, Valérie Jooste, Nicolas Champtiaux, et al.. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain - A Journal of Neurology , 2016, 139 (8), pp.2131 - 2135. ⟨10.1093/brain/aww054⟩. ⟨hal-01409979⟩
176 Consultations
0 Téléchargements

Altmetric

Partager

More